SPRYCEL for Ph+ CML in Children
How is SPRYCEL® (dasatinib) used to treat children with Ph+ CML
in chronic phase (CP)?
If your child has been diagnosed with Philadelphia–positive (Ph+) chronic myeloid leukemia (CML), you may have questions. Here, you will find details about Ph+ CML in children and its treatment with SPRYCEL.
Find out more about SPRYCEL treatment in children with Ph+ CML in CP, including:
- How children should take SPRYCEL
- How SPRYCEL has been studied in children in clinical trials
- Safety information for children taking SPRYCEL
What are some important facts about Ph+ CML in children?
- Ph+ CML is a form of leukemia, or cancer of the blood, that can affect children
- CML is a chronic form of leukemia, meaning it is “slower growing” than other leukemias
- Out of all the childhood leukemias, CML accounts for less than 3% of the total number of cases
Did you know?
Researchers discovered that the cause of Ph+ CML is connected to the Philadelphia chromosome.
This is an abnormal chromosome that contains the BCR-ABL gene, which can lead to the overproduction of white blood cells. These white blood cells are often damaged and can crowd out healthy blood cells.
This chromosome is found in almost everyone who has CML.
What is SPRYCEL?
SPRYCEL is a prescription medication used to treat children 1 year of age and older with Ph+ CML in chronic phase.
It is not known if SPRYCEL is safe and effective in children under 1 year of age.
What can we expect from treatment?
Your child’s doctor will discuss the treatment goals with you. He or she will see your child for follow-up appointments to check if your child is reaching those goals. The doctor will let you know how often your child should come for appointments, and what tests to expect.